Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether idarubicin dose intensification is safe and
effective as a remission induction therapy for acute myeloid leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Konkuk University Medical Center
Collaborators:
Chonbuk National University Hospital Chung-Ang University Hosptial, Chung-Ang University College of Medicine Ewha Womans University Hanyang University Seoul Hospital Pusan National University Hospital Samsung Medical Center Seoul National University Hospital Soon Chun Hyang University